The legal action, filed by the DJS Law Group, centers on claims that Capricor Therapeutics violated federal securities laws by issuing false and misleading statements. According to the complaint, the biotechnology firm resubmitted a Biologics License Application for Deramiocel despite failing to reach an agreement with the FDA regarding changes to the drug's clinical data analysis. These undisclosed modifications form the basis of the alleged 10b-5 violations.
Capricor Therapeutics Faces Securities Litigation Over Drug Data
Investors who purchased Capricor Therapeutics stock between December 17, 2025, and July 26, 2026, are being urged to join a class action lawsuit. The filing alleges that the company misled the market by altering statistical plans for its drug Deramiocel without securing prior FDA approval.
Shareholders seeking to participate in the litigation must act before the September 28, 2026, deadline. Attorney David J. Schwartz, who represents the firm, noted that investors do not need to be appointed as lead plaintiffs to recover potential losses. The lawsuit specifically targets breaches of the Securities Exchange Act of 1934, citing the company's failure to provide accurate disclosures regarding its regulatory interactions.
Comments (0)
No comments yet. Be the first!